Bawumia’s Big Plan for Ghana Revealed as He Meets Pharmaceutical Society Members

Ghana’s dependence on imported medicines could become a major issue in the country’s economic future, and Dr Mahamudu Bawumia appears to be putting the pharmaceutical industry at the centre of his plans for change.

The former Vice President has reportedly met members of the Pharmaceutical Society of Ghana to discuss a plan aimed at raising Ghana’s position in the pharmaceutical industry. The meeting, reported by GhanaWeb on Friday, October 23, 2026, has brought attention to the role local medicine production could play in the country’s development.

The report, titled “The Big Pill: Bawumia’s plan to put Ghana on the pharmaceutical map,” featured Bawumia meeting members of the Pharmaceutical Society of Ghana. However, the information provided does not include the full details of his proposals, the specific commitments made during the meeting or a timeline for putting the plan into action.

Nevertheless, the subject touches on an important issue for many Ghanaians: access to affordable and reliable medicines.

Ghana’s pharmaceutical sector has the potential to support job creation, strengthen local businesses and reduce some of the country’s reliance on imported medical products. A stronger local industry could also help improve the supply of essential medicines when international supply chains face problems.

For patients, the biggest concern is often the cost of treatment. Families dealing with illness can face financial pressure when medicines are expensive or difficult to find. Any serious plan to expand local production would therefore need to show how it could improve access and keep prices within reach of ordinary people.

However, making Ghana a major pharmaceutical producer would require more than political promises. Manufacturers need reliable power, modern equipment, skilled workers, access to funding and strong systems to ensure medicines meet safety standards. Investment in research and proper checks on the quality of locally produced drugs would also be essential.

Bawumia’s engagement with pharmaceutical professionals could provide an opportunity to discuss these challenges and identify practical solutions. But the real test will be whether the ideas discussed can be turned into clear policies, backed by funding and measurable targets.

The proposal also raises questions about how the government, private businesses and health professionals would work together to support the industry. Investors would need confidence that policies would remain stable, while local manufacturers would need support to compete with established producers from other countries.

Although the meeting signals interest in the sector, the available report does not provide enough detail to determine how the plan would be funded or what results it could deliver.

Dipshiot feedback-opera-news-app@opera.com